Copyright
©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Sep 21, 2021; 27(35): 5796-5802
Published online Sep 21, 2021. doi: 10.3748/wjg.v27.i35.5796
Published online Sep 21, 2021. doi: 10.3748/wjg.v27.i35.5796
Induced pluripotent stem cells as an innovative model to study drug induced pancreatitis
Elena Genova, Giuliana Decorti, Institute for Maternal and Child Health, IRCCS Burlo Garofolo, Trieste 34137, Italy
Gabriele Stocco, Department of Life Sciences, University of Trieste, Trieste 34127, Italy
Giuliana Decorti, Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste 34127, Italy
Author contributions: Genova E, Stocco G and Decorti G designed the research study, reviewed and edited the manuscript; Genova E performed the research and wrote the manuscript; all authors have read and approved the final manuscript.
Supported by Italian Ministry of Health (IRCCS Burlo Garofolo) , No. RC 7_2014 .
Conflict-of-interest statement: Authors have nothing to disclose.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Giuliana Decorti, MD, Full Professor, Institute for Maternal and Child Health, IRCCS Burlo Garofolo, Via dell’Istria 65, Trieste 34137, Italy. decorti@units.it
Received: March 17, 2021
Peer-review started: March 17, 2021
First decision: April 16, 2021
Revised: April 27, 2021
Accepted: August 30, 2021
Article in press: August 30, 2021
Published online: September 21, 2021
Peer-review started: March 17, 2021
First decision: April 16, 2021
Revised: April 27, 2021
Accepted: August 30, 2021
Article in press: August 30, 2021
Published online: September 21, 2021
Core Tip
Core Tip: About 5% of inflammatory bowel disease patients develop pancreatitis after thiopurine administration. The mechanism of this adverse effect is still not clear making it difficult to prevent. By differentiating induced pluripotent stem cells into their pancreatic exocrine counterpart, it is possible to set up innovative personalized in vitro models to study this adverse effect in a more effective way.